A coordinated seven-year national strategy aims to build global leadership in advanced medical technologies, reduce import reliance, and expand industry competitiveness
South Korea has announced an ambitious seven-year investment program worth about KRW 940 billion ($622 million) to advance high-tech medical devices and strengthen the country’s healthcare innovation ecosystem. Starting next year and continuing through 2030, the government will offer large-scale support to hospitals, research institutes, and medtech companies to accelerate the development of what officials describe as “game-changing” medical equipment.
The initiative forms the foundation of a broader pan-ministry R&D program led by the Ministry of Science and ICT together with the Ministries of Trade, Industry and Resources; Health and Welfare; and Food and Drug Safety. A total of KRW 940.8 billion, including KRW 102.5 billion from the private sector, will be deployed between 2026 and 2032 to support advanced medical device research. Officials say this coordinated investment signals strong alignment between the public and private sectors in shaping Korea’s next growth drivers in healthcare technology.
Six Strategic Fields Targeted for Breakthrough Innovation
The new plan directs investment into six high-growth sectors considered critical for Korea’s competitiveness and future medical needs. These include:
- Medical robotics
- Dental implant technologies
- Next-generation molecular diagnostic devices
In addition, the government aims to localize production of 13 essential medical devices currently reliant on imports. This move is meant to reduce external vulnerabilities and improve Korea’s medical security.
“This is a collaboration across ministries to support the development of high-tech medical devices, the country’s next growth engine,”
— Industry Ministry (press statement)
Officials noted that reducing import dependency is now seen as a core national priority, particularly after global supply chain disruptions during recent health crises.
Support Across the Full Development Cycle
The program is designed to back every stage of medical device development, ensuring that promising technologies do not stall between research, testing, and commercialization. Support will cover:
- Basic research
- Prototype development
- Clinical trials
- Regulatory processes
- Market deployment
This approach aims to shorten time-to-market and enable Korean companies to compete more effectively with global medical device giants. Special emphasis will be placed on technologies that integrate artificial intelligence, robotics, digital healthcare systems, and automated diagnostics.
Built on Strong Results From the First Phase (2020–2025)
The new initiative builds on the progress of the first phase, which ran from 2020 to 2025 and delivered measurable results. Over those five years, the government recorded:
- 433 domestic and international regulatory approvals
- KRW 185.2 billion in cumulative sales
- 445 medical device patents
- Localization of key equipment such as blood filters for artificial kidneys
One of the standout achievements was the development of the world’s first AI-powered device for diagnosing cerebral infarction, demonstrating Korea’s rapid advances in combining clinical data with AI-driven analysis.
467 Projects Supported, Significant Commercial Impact
During the initial phase, a total of 467 R&D projects received support. These efforts resulted in numerous technology transfers, real-world clinical applications, and commercialized products. Officials highlight that the early program helped Korean companies move beyond incremental improvements and into the development of globally competitive innovations.
“We will continue to gather feedback from the research community and strengthen support to ensure successful execution of this long-term strategy,”
— Government official overseeing the program
By applying lessons learned from the first phase, the Korean government expects sharper execution, more efficient use of funds, and faster commercialization outcomes in the second phase.
Enhancing National Medical Security and Global Competitiveness
As Korea launches the second phase of its strategy, the focus extends beyond technological leadership. A key objective is to improve national medical security by producing critical equipment domestically and reducing exposure to global supply risks.
Officials also emphasized that the program is designed to help Korean companies secure a larger share of international healthcare markets, particularly in fast-growing categories such as robotic surgery, precision diagnostics, and AI-enabled clinical tools.
By strengthening the entire medical device ecosystem—from R&D to commercialization—Korea aims to position itself not only as a global healthcare innovator, but as a country capable of shaping the next generation of medical technologies.
